Jun 26, 2018 - Health

The pharma industry tilt of the FDA

FDA headquarters building in Maryland.

The FDA is rejecting fewer drug applications. Photo: Al Drago/CQ Roll Call via Getty Images

The Food and Drug Administration is "increasingly green-lighting expensive drugs despite dangerous or little-known side effects and inconclusive evidence that they curb or cure disease," due in part to direct and indirect influence from the pharmaceutical industry, ProPublica reports.

The bottom line: The Trump administration says quick drug approvals benefit patients in need. But drug companies are collecting the financial rewards with high-priced medicines and few, if any, incentives to make sure their drugs are effective after they hit the market.

Go deeper